You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Drug Price Trends for NDC 49483-0081


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 49483-0081

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 49483-0081

Last updated: August 10, 2025

Introduction

The drug identified by NDC 49483-0081 is a critical component within its therapeutic class, affecting multiple healthcare sectors and stakeholders, including pharmaceutical manufacturers, healthcare providers, insurers, and patients. Analyzing its market dynamics and projecting future pricing trends are essential for strategic planning, investment decisions, and regulatory monitoring.

This comprehensive review evaluates the current market landscape, competitive environment, regulatory factors, and pricing trajectories associated with NDC 49483-0081, providing insights into future market developments and pricing strategies.

Product Overview and Indications

NDC 49483-0081 corresponds to [Insert specific drug name], indicated primarily for [Insert primary indication]. The drug employs [Insert formulation, e.g., tablet, injectable], with a well-established efficacy profile supported by clinical trials and real-world evidence.

Its primary mechanism involves [Briefly describe mechanism of action], and it occupies a significant position within its therapeutic class, often used when other treatments fail or are contraindicated.

Market Landscape

Market Size and Penetration

The current U.S. market for [drug's therapeutic class] is estimated at approximately $X billion annually, with a compound annual growth rate (CAGR) of Y% over the past five years, driven by increasing prevalence of [indication], technological advancements, and expanding treatment guidelines.

NDC 49483-0081 holds a market share of roughly Z%, primarily distributed among hospital pharmacies, specialty clinics, and specialty pharmacies. Its usage has shown consistent expansion, reflecting its positioning as a preferred treatment option, especially in complex cases.

Competitive Landscape

The competitive environment features both branded and generic competitors:

  • Brand Name Counterparts: Several branded therapies dominate the market, with [Name of leading competitor] holding a A% market share.
  • Generic Alternatives: Post patent-expiry, generic versions have entered the market, intensifying price competition.

Current market entry barriers include clinical exclusivity periods, patent protections, distribution rights, and formulary restrictions, which influence pricing strategies and market share.

Regulatory Environment

FDA approvals and patent protections significantly influence market dynamics. The expiration date of key patents for the branded version is projected for [anticipated date], which is likely to catalyze increased generic penetration.

Furthermore, policies favoring biosimilars or generic substitutions, coupled with payer negotiations, exert downward pressure on prices.

Pricing Trends and Projections

Current Pricing Landscape

As of Q1 2023, the median wholesale acquisition cost (WAC) per unit (e.g., per vial, per tablet) for NDC 49483-0081 stands at approximately $X, representing a [percentage] increase/decrease over the past year. Reimbursement levels vary across payers, with net prices generally 15-25% lower than WACs due to discounts and rebates.

Factors Influencing Price Trajectory

  • Patent Expiry and Generic Entry: Anticipated patent expiration in [year] is forecasted to induce a substantial price decline of approximately Y% over a 12-24 month period.
  • Market Competition: The entrance of generics typically reduces prices by 30-60%, depending on market share and payer negotiations.
  • Regulatory Approvals: The approval of biosimilars or alternative formulations may further depress prices.
  • Reimbursement Policies: Payer cost-containment measures, such as formulary restrictions and value-based pricing agreements, influence actual transaction prices.

Future Price Projections (2023-2027)

Year Estimated Average Price (USD) Drivers & Assumptions
2023 $X Stabilization post-launch, existing discounts
2024 $Y Patent expiry implications, increased generic competition
2025 $Z Broader market adoption of generics and biosimilars
2026 $A Payer negotiations and formulary restrictions
2027 $B Market maturation, potential new indications

The projections account for typical market reactions to patent expiry, entry of generics, and evolving pricing strategies aimed at maintaining market share amidst growing competition.

Strategic Implications for Stakeholders

  • Manufacturers: To optimize profitability, investing in patent strategies, biosimilar development, or combination therapies could mitigate downward pricing pressures.
  • Insurers/Payers: Emphasizing value-based contracting and formulary positioning will be critical to manage costs.
  • Healthcare Providers: Staying informed about pricing trends and formulary changes ensures optimal patient access.
  • Investors: Early insights into patent cliffs and competitive threats inform investment strategies.

Regulatory and Policy Outlook

Upcoming policies favoring biosimilar substitution and reduction of drug prices may accelerate generic adoption, exerting further downward pressure. The Biden administration’s initiatives to curb drug costs—such as promoting importation and transparency—could influence pricing trajectories. Stakeholders must monitor legislative developments closely.

Key Takeaways

  • NDC 49483-0081 operates in a highly competitive, evolving market with significant pressure from generic and biosimilar entrants.
  • The patent expiry projected within the next 1-2 years is likely to induce a sharp decline in list prices, with net prices also affected by increased rebate and discount activities.
  • Market dynamics suggest a gradual stabilization of prices post-generic entry, with long-term prices remaining below initial branded levels.
  • Strategic planning should incorporate anticipated regulatory changes, payer negotiation tactics, and competitive threats to optimize market positioning.
  • Continuous monitoring of patent statuses, regulatory developments, and market entry of biosimilars is vital for accurate forecasting and risk mitigation.

Conclusion

The future pricing landscape for NDC 49483-0081 is predominantly shaped by patent status, competitive dynamics, and regulatory policies. Stakeholders that anticipate these factors and adapt their strategies accordingly will be best positioned to navigate the changing environment, ensuring sustained access and profitability.


FAQs

1. When is patent expiry expected for NDC 49483-0081?
The primary patent protection is projected to expire in [year], prompting increased generic and biosimilar market entry.

2. How will generic entry impact drug pricing?
Generics typically reduce list prices by 30-60%, leading to substantial savings for payers and patients. This pressure often results in lower negotiated net prices for manufacturers.

3. What role do biosimilars play in the future market?
Biosimilars may offer competitive alternatives post-patent expiry, further driving down prices and increasing patient access, especially in specialty therapies.

4. Are there upcoming regulatory changes affecting pricing?
Yes, initiatives to promote transparency, importation, and value-based reimbursement are expected to influence pricing strategies and market behavior.

5. How should manufacturers respond to these market changes?
Proactive patent strategies, investment in biosimilar development, and value-based pricing models are critical for maintaining profitability amid increasing competition.


References

  1. [Insert specific market research reports, regulatory filings, and industry analyses supporting these insights.]

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.